Bélanger G L, Lavallée J P, Lenis J, Ouellet C A
Can J Cardiol. 1985 Mar;1(2):97-105.
The institution of a "Cardioprophylactic" drug regimen after myocardial infarction should take into consideration the concept of high or low risk patients for secondary coronary events and the concept of a decremential mortality rate as time elapses after myocardial infarction. Thus, the efficacy of a particular drug in preventing secondary coronary events may vary with the time elapsed from infarction and thus with the underlying patho-physiologic mechanism. Furthermore, the administration of a possible effective or proven effective "Cardioprophylactic" drug or drug regimen at a specific time from infarction must take into account the balance between expected benefit and untoward side effects.
心肌梗死后采用“心脏预防”药物治疗方案时，应考虑继发性冠状动脉事件高危或低危患者的概念，以及心肌梗死后随着时间推移死亡率递减的概念。因此，特定药物预防继发性冠状动脉事件的疗效可能会随心肌梗死后经过的时间而变化，进而随潜在的病理生理机制而变化。此外，在心肌梗死后的特定时间给予可能有效或已证实有效的“心脏预防”药物或药物治疗方案时，必须考虑预期获益与不良副作用之间的平衡。
